This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (20)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Metabolic Diseases  • Prognosis/ Outcomes  • Drug Therapy, Other  • Hypertension  • Alert me on articles by topic  Social Bookmarking   What's this?

Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

Jackson T. Wright Jr, MD, PhD; Sonja Harris-Haywood, MD; Sara Pressel, MS; Joshua Barzilay, MD; Charles Baimbridge, MS; Charles J. Bareis, MD; Jan N. Basile, MD; Henry R. Black, MD; Richard Dart, MD; Alok K. Gupta, MD; Bruce P. Hamilton, MD; Paula T. Einhorn, MD, MS; L. Julian Haywood, MD; Syed Z. A. Jafri, MD; Gail T. Louis, RN, BA; Paul K. Whelton, MD, MSc; Cranford L. Scott, MD; Debra L. Simmons, MD; Carol Stanford, MD; Barry R. Davis, MD, PhD

Arch Intern Med. 2008;168(2):207-217.

Background  Antihypertensive drugs with favorable metabolic effects are advocated for first-line therapy in hypertensive patients with metabolic/cardiometabolic syndrome (MetS). We compared outcomes by race in hypertensive individuals with and without MetS treated with a thiazide-type diuretic (chlorthalidone), a calcium channel blocker (amlodipine besylate), an -blocker (doxazosin mesylate), or an angiotensin-converting enzyme inhibitor (lisinopril).

Methods  A subgroup analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), a randomized, double-blind hypertension treatment trial of 42 418 participants. We defined MetS as hypertension plus at least 2 of the following: fasting serum glucose level of at least 100 mg/dL, body mass index (calculated as weight in kilograms divided by height in meters squared) of at least 30, fasting triglyceride levels of at least 150 mg/dL, and high-density lipoprotein cholesterol levels of less than 40 mg/dL in men or less than 50 mg/dL in women.

Results  Significantly higher rates of heart failure were consistent across all treatment comparisons in those with MetS. Relative risks (RRs) were 1.50 (95% confidence interval, 1.18-1.90), 1.49 (1.17-1.90), and 1.88 (1.42-2.47) in black participants and 1.25 (1.06-1.47), 1.20 (1.01-1.41), and 1.82 (1.51-2.19) in nonblack participants for amlodipine, lisinopril, and doxazosin comparisons with chlorthalidone, respectively. Higher rates for combined cardiovascular disease were observed with lisinopril-chlorthalidone (RRs, 1.24 [1.09-1.40] and 1.10 [1.02-1.19], respectively) and doxazosin-chlorthalidone comparisons (RRs, 1.37 [1.19-1.58] and 1.18 [1.08-1.30], respectively) in black and nonblack participants with MetS. Higher rates of stroke were seen in black participants only (RR, 1.37 [1.07-1.76] for the lisinopril-chlorthalidone comparison, and RR, 1.49 [1.09-2.03] for the doxazosin-chlorthalidone comparison). Black patients with MetS also had higher rates of end-stage renal disease (RR, 1.70 [1.13-2.55]) with lisinopril compared with chlorthalidone.

Conclusions  The ALLHAT findings fail to support the preference for calcium channel blockers, -blockers, or angiotensin-converting enzyme inhibitors compared with thiazide-type diuretics in patients with the MetS, despite their more favorable metabolic profiles. This was particularly true for black participants.

Trial Registration  clinicaltrials.gov Identifier: NCT00000542

Author Affiliations: Department of Medicine, General Clinical Research Center (Dr Wright), and Department of Family Medicine, Case Western Reserve University (Dr Harris-Haywood), Cleveland, Ohio; Coordinating Center for Clinical Trials, School of Public Health, The University of Texas Health Science Center at Houston (Ms Pressel, Mr Baimbridge, and Dr Davis); Kaiser Permanente of Georgia, Tucker (Dr Barzilay); Department of Medicine, MacNeal Center for Clinical Research, Berwyn, Illinois (Dr Bareis); Ralph H. Johnson Veterans Affairs Medical Center and Medical University of South Carolina, Charleston (Dr Basile); Section of Cardiology, Department of Internal Medicine, New York University School of Medicine, New York (Dr Black); Department of Nephrology, Marshfield Clinic, Marshfield, Wisconsin (Dr Dart); Pennington Biomedical Research Center, Baton Rouge, Louisiana (Dr Gupta); Hypertension-Endocrine Unit, Veterans Affairs Medical Center, Baltimore, Maryland (Dr Hamilton); Division of Prevention and Population Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland (Dr Einhorn); Division of Cardiovascular Medicine, University of Southern California Medical Center, Los Angeles (Dr Haywood); Department of Cardiology, Veterans Affairs Medical Center, Fargo, North Dakota (Dr Jafri); Tulane University Health Sciences Center, New Orleans, Louisiana (Ms Louis); Loyola University Medical Center, Maywood, Illinois (Dr Whelton); Cranford L. Scott, MD, Inc, Inglewood, California (Dr Scott); Department of Endocrinology, University of Arkansas for Medical Sciences, Little Rock (Dr Simmons); and University of Missouri Kansas City School of Medicine (Dr Stanford).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Management of Blood Pressure for Acute and Recurrent Stroke
Aiyagari and Gorelick
Stroke 2009;40:2251-2256.
FULL TEXT  

ALLHAT Findings Revisited in the Context of Subsequent Analyses, Other Trials, and Meta-analyses
Wright et al.
Arch Intern Med 2009;169:832-842.
ABSTRACT | FULL TEXT  

National Heart, Lung, and Blood Institute-Initiated Program "Interventions to Improve Hypertension Control Rates in African Americans": Background and Implementation
Einhorn
Circ Cardiovasc Qual Outcomes 2009;2:236-240.
FULL TEXT  

Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum.
Cooper-DeHoff et al.
J Am Coll Cardiol 2009;53:S28-S34.
ABSTRACT | FULL TEXT  

The Metabolic Syndrome
Cornier et al.
Endocr. Rev. 2008;29:777-822.
ABSTRACT | FULL TEXT  

The choice of antihypertensive therapy in patients with the metabolic syndrome--time to change recommendations?
Hilgers and Mann
Nephrol Dial Transplant 2008;23:3389-3391.
FULL TEXT  

Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes
Triplitt and Alvarez
Diabetes Spectr. 2008;21:177-189.
ABSTRACT | FULL TEXT  

Thiazide-Induced Dysglycemia: Call for Research From a Working Group From the National Heart, Lung, and Blood Institute
Carter et al.
Hypertension 2008;52:30-36.
FULL TEXT